Zacks: Brokerages Expect Replimune Group Inc (NASDAQ:REPL) to Post -$0.37 Earnings Per Share

Wall Street analysts expect Replimune Group Inc (NASDAQ:REPL) to announce ($0.37) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Replimune Group’s earnings, with estimates ranging from ($0.42) to ($0.31). Replimune Group reported earnings per share of ($0.24) in the same quarter last year, which would suggest a negative year-over-year growth rate of 54.2%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 13th.

On average, analysts expect that Replimune Group will report full year earnings of ($1.38) per share for the current year, with EPS estimates ranging from ($1.52) to ($1.26). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.89) to ($1.31). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Replimune Group.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Monday, November 11th. The company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01).

A number of equities analysts recently issued reports on the company. ValuEngine upgraded Replimune Group from a “hold” rating to a “buy” rating in a research note on Wednesday. Chardan Capital reiterated a “buy” rating and set a $28.00 price target on shares of Replimune Group in a research note on Thursday, October 24th. Zacks Investment Research lowered Replimune Group from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Wedbush reduced their price objective on Replimune Group from $30.00 to $12.50 and set an “outperform” rating for the company in a research note on Wednesday, November 20th. Finally, Roth Capital raised their price objective on Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $23.25.

In other news, CEO Robert Coffin sold 24,250 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $17.05, for a total value of $413,462.50. Also, Director Jason P. Rhodes bought 1,100,000 shares of the stock in a transaction dated Monday, November 18th. The stock was bought at an average price of $13.61 per share, for a total transaction of $14,971,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 1,335,000 shares of company stock worth $18,016,500 and sold 200,000 shares worth $3,395,500. 63.18% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of REPL. Squarepoint Ops LLC boosted its holdings in Replimune Group by 34.6% during the third quarter. Squarepoint Ops LLC now owns 21,799 shares of the company’s stock worth $303,000 after buying an additional 5,599 shares in the last quarter. Morgan Stanley increased its holdings in Replimune Group by 793.0% in the second quarter. Morgan Stanley now owns 20,709 shares of the company’s stock valued at $304,000 after buying an additional 18,390 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Replimune Group by 211.3% in the second quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock valued at $338,000 after buying an additional 15,672 shares in the last quarter. Northern Trust Corp raised its position in shares of Replimune Group by 1.2% in the second quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock worth $1,817,000 after acquiring an additional 1,437 shares during the period. Finally, State Street Corp raised its position in shares of Replimune Group by 6.0% in the third quarter. State Street Corp now owns 183,687 shares of the company’s stock worth $2,553,000 after acquiring an additional 10,406 shares during the period. 56.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of REPL opened at $13.88 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.85 and a quick ratio of 9.85. The company’s fifty day moving average price is $14.72 and its 200-day moving average price is $13.22. Replimune Group has a 1-year low of $8.88 and a 1-year high of $18.25.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: What is Call Option Volume?

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.